Abstract
Administration of more than 400 mg/day of sorafenib for 1 month prolonged progression-free survival (PFS) in Japanese patients with advanced renal cell carcinoma (RCC). This indicated that it is very important to prevent and manage side effects of sorafenib avoiding drug withdrawal or dose reduction. I mention the side effects of sorafenib and countermeasures in this review.
MeSH terms
-
Antineoplastic Agents / adverse effects*
-
Carcinoma, Renal Cell / drug therapy*
-
Humans
-
Kidney Neoplasms / drug therapy*
-
Molecular Targeted Therapy / adverse effects*
-
Niacinamide / adverse effects
-
Niacinamide / analogs & derivatives*
-
Phenylurea Compounds / adverse effects*
-
Sorafenib
Substances
-
Antineoplastic Agents
-
Phenylurea Compounds
-
Niacinamide
-
Sorafenib